Skip to content
i2E
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Menu
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

Oklahoma-based Kirrhos Pharmaceuticals tackles fatty liver disease known as NASH

Get in Touch

By Scott Meacham
Copyright © 2019, The Oklahoman

When a looming medical problem exists, people usually hear about it — so much so that even lay people become familiar with the scientific names — angina, arrhythmia, blastoma, lymphoma, hepatitis and the like.

Cirrhosis, the condition of scarring and permanent damage to the liver, often from alcohol, is another liver condition often in the public eye. Less commonly known beyond the medical profession, however, are the underlying causes of cirrhosis that are not related to hepatitis or alcohol.

Two of those conditions are nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)—conditions, which are related to too much fat being stored in the liver occurring in people who do not drink.

In the U.S., NAFLD affects an estimated 80 million people. NASH, an especially aggressive form of NAFLD which results in inflammation, liver damage, liver scarring, cirrhosis, and liver cancer caused by fat building up in the liver, is projected to be the leading cause of liver transplant by 2020.

There are no silver bullets in tackling the problem of liver disease. It is very complicated and often involves a multi-pronged approach, tackling diabetes, cardiovascular issues, and more simultaneously. There are drug therapies for these, but there is no drug therapy for fatty liver disease.

Kirrhos Pharmaceuticals, an Oklahoma-based biotechnology firm is developing an oral drug to treat and reverse the effects of fatty liver disease. With a streamlined development plan, the company expects to put the drug in clinical trials in less than 15 months.

“The beginning stages of fatty liver disease are reversible,” said Dr. Elaine Hamm, Kirrhos Pharmaceuticals Founder and COO. “If you catch it early, you can stop it. But one of the most frightening aspects of NAFLD is that it is silent. A person can have NAFLD without knowing it, until it progresses to an advanced stage. By then, irreversible liver damage is done.”

Creating awareness, is top of mind for Dr. Hamm and Kirrhos Pharmaceuticals.

“Fatty liver disease is a big medical problem and is emerging as one of the most common chronic liver diseases.” she said. “Unfortunately, though millions of Americans are at risk for developing this disease, they may not even know it. Patients need to know about NAFLD and NASH and have meaningful conversations with their physicians early about the dangers of this disease, their own risk factors, and about the impact of diet and exercise on preventing liver damage.’

Beyond creating therapies that reverse disease, it is critically important that early stage biotech startups are “canaries in the coal mine.”

As these young companies dig into unsolved problems to improve and save lives, they also play a unique and vital role in education and awareness—especially when it comes to conditions like fatty liver disease which can affect so many in such life-threatening ways. (For more information, visit the Ascend BioVentures website)

Scott Meacham is president and CEO of i2E Inc., a nonprofit corporation that mentors many of the state’s technology-based startup companies. i2E receives state appropriations from the Oklahoma Center for the Advancement of Science and Technology. Contact Meacham at i2E_Comments@i2E.org

Author

  • Sarah Graves Sarah Graves

More News

Loading...
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma State University BIO

Read more
Default Featured Image
OKBio
06.13.22

ECHO Investment Capital BIO

Read more
Default Featured Image
OKBio
06.13.22

AscendBioVentures BIO

Read more
Default Featured Image
OKBio
06.13.22

Dean McGee Eye Institute BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2022 i2E Privacy Policy

Follow us:

Facebook Twitter Linkedin

Programs

  • E3
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E